Breaking News

Debiopharm Group Plans Expansion

By Kristin Brooks | March 6, 2014

Aims to acquire opportunities for optimization and production of complex drugs

Debiopharm Group has plans to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its development and production facility in Martigny, Switzerland, through the acquisition of industrial high-value added activities or companies in the pharma, biopharma or medical technology field.

Debiopharm Research & Manufacturing provides chemical synthesis, formulation development and manufacturing. The company aims to acquire opportunities for optimization and production of complex pharmaceutical products, with modern infrastructure combined with high-tech GMP production, a logistic platform for worldwide delivery, established quality assurance and regulatory certification, as well as a central location in Europe.

"We want to be the bridge between development and industrialization, and supply Swiss-made products manufactured using state-of-the-art technology, said Cedric Sager, chief executive officer of Debiopharm Research & Manufacturing. “Hard-to-make drugs, highly complex formulated drugs, biologic niche products, premium diagnostics and medical devices are on our wish-list."

Thierry Mauvernay, delegate of the board of Debiopharm Group, said, "We have invested heavily during the last years to automate our site in Martigny as much as possible. Thanks to our efforts, we have increased our productivity. Our wish now is to acquire new industrial opportunities to strengthen our activity in Valais and support our development.”

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO